CAR-T On-Target Off-Tumor Toxicity Assessment Service

Online Inquiry

Background Service What We Can Offer Workflow HighlightsFAQs Contact

CAR-T cell therapy faces significant clinical hurdles due to on-target, off-tumor toxicity, where engineered T cells attack healthy tissues expressing similar antigens, leading to severe organ damage and potential trial failure. Creative Biolabs' CAR-T On-Target Off-Tumor Toxicity Assessment Service is designed to systematically evaluate and mitigate this critical risk early in development. Utilizing high-fidelity human induced pluripotent stem cell (hiPSC)-derived tissue models and advanced affinity-profiling platforms, we provide physiologically relevant, human-specific preclinical data. This enables you to de-risk candidate selection, optimize therapeutic windows, and strengthen regulatory submissions by delivering robust, human-predictive safety assessments.

Introduction

On-target, off-tumor toxicity remains a major challenge in CAR-T cell therapy, as normal cells expressing similar antigens can be attacked, leading to organ damage. Current NSCLC targets include MSLN, EGFR, ROR1, MUC1, PSCA, and HER2, while emerging antigens like LUNX and B7-H3 show promise due to their tumor-restricted expression. To mitigate this toxicity, several strategies are being explored: pre-blocking antigen sites on normal tissues, reducing scFv affinity, engineering inhibitory or dual-target CAR-T cells, and developing locally activatable CAR-T cells. These approaches aim to enhance safety without compromising antitumor efficacy.

Fig.1 Navigating treatment-related toxicity and on-target, off-tumor effects in CAR-T cell therapy. (OA Literature) Fig.1 Toxicities associated with CAR-T cell therapy: on-target/off-tumor events and intervention strategies.¹

CAR-T On-Target Off-Tumor Toxicity Assessment Service at Creative Biolabs

Creative Biolabs provides a comprehensive suite of human-relevant assays designed to identify potential toxicities before they reach the clinic. We specialize in detecting "hidden" antigen expression in vital organs that animal models often miss due to species-specific expression patterns. By utilizing our platform, you receive a detailed safety profile that directly informs dose escalation and patient selection strategies.

What We Can Offer

Our CAR-T On-Target Off-Tumor Toxicity Assessment Service provides a comprehensive, human-relevant testing suite to de-risk your CAR-T cell therapy by predicting and quantifying potential adverse effects on healthy tissues.

Featured services of CAR-T OTOT toxicity assessment service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

The CAR-T cell construct (or sequence).
Specific binder information.
Prioritized "off-target" organs of concern based on target expression profiles.

Key Steps:

Workflow of CAR-T OTOT toxicity assessment service at Creative Biolabs. (Creative Biolabs Original)

Estimated Timeframe: The standard project timeline typically spans 6 to 10 weeks. The specific duration is contingent upon the intricacy of the required tissue models and the total number of CAR constructs undergoing comparative evaluation.

Key Advantages

Human-Relevant hiPSC Model Platform: Our service provides access to an extensive, validated library of hiPSC-derived functional cell types, such as cardiomyocytes, hepatocytes, and neurons, enabling precise simulation of human tissue-specific, on-target off-tumor (OTOT) toxicity risks.
Targeted Affinity Optimization & Therapeutic Window Profiling: We perform systematic codon optimization and iterative affinity tuning of your CAR construct, delivering data to define the critical therapeutic window that balances potent tumor cytotoxicity against minimal off-target T-cell sequestration.
End-to-End De-risking Workflow: We offer a complete, integrated safety assessment pipeline, from initial proof-of-concept pilot studies to automated, high-throughput screening of multiple CAR candidates, supporting data-driven lead selection and development decisions.

FAQs

Q1: What is the advantage of employing hiPSC-derived models over conventional animal studies for OTOT evaluation?

A1: Animal models are frequently limited by cross-species differences in target antigen sequences and expression patterns. Our hiPSC-derived human tissue models express the native, full-length human protein targets, thereby providing a species-relevant, high-fidelity platform to accurately assess the risk of your CAR construct binding to unintended healthy tissues.

Q2: Does your platform have the capability to assess potential delayed adverse effects that manifest post-infusion?

A2: Absolutely. We have established extended longitudinal co-culture systems that support the sustained monitoring of CAR-T cell viability, persistence, and functional activity alongside tissue health for up to 28 days. This extended timeline is critical for modeling the "persistence paradox," where durable therapeutic cells may also pose a risk of late-onset toxicity.

Why Choose Us?

We uniquely integrate the latest clinical insights, such as delayed neurotoxicity and affinity-dependent sequestration, into a human-relevant "Bedside-to-Bench" testing paradigm. Our platform utilizes hiPSC-derived human tissues and advanced co-culture systems to accurately assess cross-reactivity and functional toxicity against native human antigen sequences, providing a critical safety bridge from CAR design to clinical translation.

Customer Reviews

"Superior Sensitivity in Neurotoxicity Detection. Using Creative Biolabs' hiPSC-derived neural models in our research has significantly improved our ability to detect low-level antigen cross-reactivity that was completely absent in our NHP studies."

— Dr. A***n L.

"Crucial for Solid Tumor Lead Selection. The 3D organoid co-culture system facilitated our understanding of CAR-T sequestration in the liver, helping us choose a binder with a better therapeutic index."

— Prof. M*ei W.

"Reliable Cytokine Profiling. The integrated secretome analysis using the CAR-T Toxicity Service significantly improved our CRS risk assessment for a novel bispecific construct."

— Dr. J*mes S.

How to Contact Us?

To obtain a customized project proposal and quotation for our CAR-T Off-Tumor Toxicity Assessment Service, please contact our cell therapy safety specialists. We will promptly schedule a technical consultation to discuss your specific CAR construct, target organs, and project timeline, providing a tailored solution to de-risk your clinical development.

Reference

Xiao, Bu-Fan et al. "Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges." Frontiers in immunology vol. 12 782775. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.782775.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.